ESC 2024: Study highlights potential for Novartis to differentiate in HF space
There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations and mortality.
There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations and mortality.
What's Your Reaction?
